[
  {
    "chunk_id": 0,
    "text": "Review Article Nutrition Management in Geriatric Patients with chronic kidney disease Lale Ertuglu and T. Alp Ikizler Sarcopenia, defined as age-related decline in skeletal muscle mass and functional capacity, is a hallmark nutritional abnormality observed in patients with moderate-to-advanced chronic kidney disease. Uremic state and associated medicalconditionsalsopredisposeolderpatientswithCKDtoproteinenergywasting, anutritionalabnormality that could include sarcopenia. Prevention of Protein and energy depletion and replenishing the already Low nutritionalreserveselderlypatientswithCKDshouldfocusonconventionalandinnovativestrategies. Thisreview aimstoprovideanoverviewofthemainstayofnutritionaltherapyinthispatientpopulation, suchasintakeof adequate amounts of Protein and energy along with preserving fluid, electrolyte, and mineral balance, and to discuss more innovative interventions to aid these approaches. KIDNEY360 5: 310319, 2024. doi: Introduction chronicinflammation, oxidativestress, anduremia, imNutritional management is one of the most important pairantiagingmechanismsandpromoteaging. 2Asigaspects of health in patients with chronic kidney disease, especially in nificantconsequence of thisprocessis poor nutritional oneswithmoderate-to-advancedstage. Theincreasing status and accelerated muscle wasting. Both advanced risk of Proteinenergy wasting is well established in Kidney disease and increasing age are associated with these vulnerable patients and stems from various facnet Protein catabolism and progressive muscle loss, tors including but not limited to inadequate dietary whichareexacerbatedbyinadequatenutritionalintake nutrient intake relative to increased needs, concurrent frequently observed in elderly patients with chronic kidney disease. metabolic abnormalities leading to altered nutrition Sarcopeniaandproteinenergywastingaretworeutilization, and the detrimental effects of Kidney related but distinct terminologies commonly used to placementtherapiesonnutritionalstatusandmetabolic describe the loss of muscle mass and function seen milieu. chronic kidney disease isalsoa diseaseofthe agingpopulation, inelderlypatientswithCKD. Sarcopeniaisdefinedas whoareindependentlyatriskofproteinenergywastage-related decline in skeletal muscle mass and funcingandsarcopenia. Whilesomeofthefactorsthatlead tional capacity and is a hallmark nutritional characto these derangements overlap between chronic kidney disease and agteristicofaging. 3, 4Variousdifferentdiagnosticcriteria ing, there are distinct elements associated with each are available to define sarcopenia, including the Eucondition, which in combination could exponentially ropean Working Group on Sarcopenia in Older Peoincrease the risk of poor clinical outcomes, such as ple5andInternationalWorkingGrouponSarcopenia. 6 cardiovascular disease, infection risk, and frailty. In These criteria identify sarcopenia on the basis of crithis review, we will discuss epidemiology of proteria such as Low overall or appendicular skeletal teinenergywasting(protein-energy wasting)intheelderlypatientswith muscle mass in conjunction with poor functional stachronic kidney disease and provide insights into the mechanisms that tus. Accordingly, the estimated prevalence of sarcolead to this abnormal state. We will also discuss the peniaisaround10%inthehealthypopulationaged60 strategies aimed at preventing and treating protein-energy wasting, inyears and older. 7 Sarcopenia is substantially more cludingrecommendationsformanagingfluidandelecprevalent among patients with chronic kidney disease. In a crosstrolyte balance in elderly patients with chronic kidney disease. sectional study by Lamarca et al. , the prevalence of sarcopeniavariedbetween4%and63%dependingon the definition of sarcopenia in patients aged 60 years Epidemiology of protein-energy wasting and Sarcopenia in Elderly and older on maintenance hemodialysis while the Patients with chronic kidney disease prevalence of decreased muscle strength was found Aging is generally measured with chronologic age, to be 85%. 8 The methods used to define Low muscle andolderageismostcommonlydefinedas65yearsor mass included appendicular lean mass index meaolder. 1 However, the relationship between aging and suredbydual-energyx-rayabsorptiometry; leanbody CKDbecomesmoreintricatebecauseoftheoccurrence massindex(body mass index)measurebybioelectricalimpedance of premature aging induced by Kidney disease itself. or skinfold thickness; mid-arm muscle circumference, Indeed, systemiccomplicationsseeninCKD, including calf circumference, and muscle function assessed by DivisionofNephrologyandHypertension, DepartmentofMedicine, VanderbiltUniversityMedicalCenter, Nashville, Tennessee Correspondence: Dr. T. AlpIkizler, DepartmentofMedicine, DivisionofNephrologyandHypertension, VanderbiltUniversityMedical Center, 116121stAvenueSouth, S-3223MedicalCenterNorth, Nashville, TN37232. Email: alp. ikizlervumc. org Copyright2024TheAuthor(s). PublishedbyWoltersKluwerHealth, Inc. onbehalfoftheAmericanSocietyofNephrology. Thisisan openaccessarticledistributedunderthetermsoftheCreativeCommonsAttribution-NonCommercial-NoDerivativesLicense4. 0 (CCBY-NC-ND), whereitispermissibletodownloadandsharetheworkprovideditisproperlycited. Theworkcannotbechangedinany wayorusedcommerciallywithoutpermissionfromthejournal. 310 www. kidney360. orgVol5February, 2024 KIDNEY3605: 310319, February, 2024 NutritioninGeriatricPatientswithCKD, ErtugluandIkizler 311 handgrip strength. 8 The prevalence of sarcopenia defined chronic disease states, including chronic kidney disease. Inflammation is a withtheEuropeanWorkingGrouponSarcopeniainOlder well-established promoter of muscle Protein breakdown Peoplecriteriausingleanmassindexandhandgripstrength leading to sarcopenia. 19 Among 328 patients with end-stage kidney disease, was 37% in another multicenter observational study.",
    "word_count": 593,
    "char_count": 5906,
    "sentence_count": 37,
    "metadata": {
      "source_file": "c3c3c7a683d3d739499c83c2d7b1fbd2a1e0.pdf",
      "extraction_date": "2025-12-31T14:48:10.990845",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2024",
      "keywords": [
        "chronic kidney disease",
        "CKD",
        "dialysis",
        "nephrology"
      ],
      "chunk_index": 0,
      "total_chunks": 9,
      "position": "1/9",
      "content_type": "dietary",
      "content_type_confidence": 6,
      "medical_entities": [
        "chronic kidney disease",
        "nutrition",
        "nutrient intake",
        "hemodialysis",
        "cardiovascular disease"
      ],
      "entity_count": 5
    }
  },
  {
    "chunk_id": 1,
    "text": "19 Among 328 patients with end-stage kidney disease, was 37% in another multicenter observational study. 9 the prevalence of High serum c-reactive Protein and IL-6 PEWreferstothelossofbodyproteinandfuelreserves wassignificantlyhigheramongpatientswithPEW, defined associated with Kidney disease. Diagnosis of protein-energy wasting is hisasSubjectiveGlobalAssessment(SGA)score. 1, indepentorically based on the presence of Low serum biomarkers dent of body mass index. In multivariate analysis, presence of inflam- (e. g. , serum albumin or transthyretin), decrease in body mation defined as c-reactive Protein 10 magnesium/L was a weight or muscle mass (e. g. , reduced mid-arm muscle cirsignificantpredictorofPEW. 20Similarly, inastudyincludcumference), orweightlosswithreducedintakeofprotein ing100patientswithCKDnotondialysis, highsensitivity andenergy. 10ThedevelopmentofPEWinCKDisdrivenby c-reactive Protein levels were inversely associated with many contributing factors, which include but not are limappendicular lean mass adjusted for body mass index while IL-4, an itedtopoornutritionalintake, systemicinflammation, and anti-inflammatory marker, was positively correlated with dialytictherapies, as well as factorsthat lead to the devellower extremity lean mass. 21 Metabolic acidosis in adopment of sarcopenia in older patients with chronic kidney disease. vanced Kidney disease further aggravates muscle Protein The prevalence of protein-energy wasting significantly rises as the disease catabolism and is a factor that can be alleviated with oral progresses, withratesincreasingfrom, 2%inCKDstages bicarbonatesupplementation. Maintenancedialysisisama12to11%54%inCKDstages35. 11Presenceorabsenceof jor catabolic procedure that increases energy and Protein protein-energy wasting is one of the strongest predictors of poor clinical requirements through nutrient loss from the hemodialysis outcomes, including declining Kidney function, hospitalimembranes and increased inflammation from indwelling zation, and mortality among patients with CKD1215 and cathetersandbioincompatiblemembranes. Variouscomorhas been associated with a two-fold increase in mortality biditiesseeninpatientswithCKD, includingdiabetesmelrisk in patients on maintenance hemodialysis. 14 Careful litusandgastrointestinaldisturbances, mayfurtherreduce nutritional management is essential in preventing the dedietary nutrient intake relative to the needs. velopmentofPEWandrelatedmorbidityandmortalityin Aging is similarly associated with loss of appetite and elderly patients with chronic kidney disease. With the rapidly aging popureducedfoodintakeinthegeneralpopulationwithoutCKD, lationandincreasingburdenofCKD, age-andCKD-related termed anorexia of aging. 22 Loss of smell and taste with poor nutrition continues to be one of the main aspects of increasingagenegativelyaffectsappetiteandvarietyofthe management in patients with Kidney disease. diet. Abnormalities in gastric motility and slower gastric emptying seen in the elderly lead to early satiety. Chronic Low-grade inflammation, hormonal changes, and increased Etiology of protein-energy wasting and Sarcopenia in Elderly Patients catabolismalsocontributetopoornutritionalstatusinolder with chronic kidney disease persons. Furthermore, nutritionalintakeintheelderlycanbe A multitude of mechanisms are related to the developaffectedbymanyfactorsincludingproblemswithchewing, ment of protein-energy wasting in advanced Kidney disease (discussed in physical function impairment, cognitive dysfunction, acute detail in refs. 16 and 17) (Figure 1). A common cause is andchronicdiseases, lowsocioeconomicstatus, depression, decreased dietary intake due to anorexia affecting up to and other social and environmental conditions. 2224 40% of patients on maintenance Dialysis. 18 Patients with earlierCKDstagesalsospontaneouslydecreasetheircaloric intakeasthediseaseprogresses. Decliningkidneyfunction Nutritional Screening and Assessments in Elderly leads to metabolic alterations that result in suppression of Patients with chronic kidney disease appetite and changes in taste perception. Presence of sysAssessmentofnutritionalstatusiscrucialforidentifying temic inflammation is also associated with anorexia in poor nutritional intake and protein-energy wasting and guiding nutritional Mechanisms of Protein Energy Wasting in chronic kidney disease Dialysis-Associated Catabolism Comorbidities -Cardiovascular Disease Sarcopenia -Diabetes Decreased -Depression -Oxidative Stress Dietary -Inflammation Nutrient Intake -Insulin Resistance Uremic Toxins Mitochondrial dysfunction Metabolic Derangements Proteinenergy -Mineral and bone disease Wasting -Metabolic Acidosis -IGF-1, GH Resistance Figure1. MechanismsofproteinenergywastinginCKD. DEI, dailyenergyintake; DPI, dailyproteinintake; GH, growthhormone: IDPN, intradialyticparenteralnutrition; IGF-1, insulin-likegrowthfactortype1; ONS, oralnutritionalsupplementation; SGA, SubjectiveGlobal Assessment. 312 KIDNEY360 therapy. Varioustoolsareavailableforassessingnutritional nutrition therapy, tailors the dietary intervention on the status and protein-energy wasting with limited evidence to recommend one basisofnutritionalassessment, comorbidities, andindividover another. The National Kidney Foundation Disease ualneeds. Medicalnutrition therapy includesthedetermiOutcomes Quality Initiative Clinical Practice Guideline nation of barriers to adequate nutritional intake, offers forNutritioninCKD: 2020Updateprovidesacomprehennutritional education, and focuses on behavioral change.",
    "word_count": 594,
    "char_count": 5573,
    "sentence_count": 32,
    "metadata": {
      "source_file": "c3c3c7a683d3d739499c83c2d7b1fbd2a1e0.pdf",
      "extraction_date": "2025-12-31T14:48:10.990845",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2024",
      "keywords": [
        "chronic kidney disease",
        "CKD",
        "dialysis",
        "nephrology"
      ],
      "chunk_index": 1,
      "total_chunks": 9,
      "position": "2/9",
      "content_type": "dietary",
      "content_type_confidence": 6,
      "medical_entities": [
        "chronic kidney disease",
        "kidney function",
        "magnesium",
        "nutrition",
        "diet",
        "nutrient intake",
        "insulin",
        "dialysis",
        "hemodialysis",
        "acidosis"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 2,
    "text": "sivelistofpotentialassessmentmethods, assummarizedin A retrospective analysis conducted in the United States Table1. ForthegeriatricpatientswithCKD, acombination investigated the survival benefit of dietitian involvement ofmethodsreadilyavailablewithinthecliniccanbeused. before the onset of end-stage kidney disease in older patients (aged 67 years Routine screening for nutritional status should be conandolder). The studycohortconsisted of156, 440patients, ducted at least biannually in patients with chronic kidney disease 35D. with88%receivingnodietitiancareandonly3%receiving Factorsthatarecommonlyencountered inelderlypatients dietitiancareformorethan1yearbeforeinitiatingdialysis. and indirectly affect nutritional intake, such as medication Compared with patients with no dietitian care, patients use, knowledge, cognitive function, behavior, access to with over 1 year of predialysis dietitian care had signififood, anddepression, shouldbeincludedintheassessment. cantlyhigherserumalbuminconcentrationsatinitiationof On the basis of the recommendations of the National Kidmaintenance Dialysis. Among patients with the second ney Foundation Disease Outcomes Quality Initiative 2020 tertile of propensity score for dietitian care, over 1 year guidelines, thepreferredapproachistousecomprehensive ofpredialysisdietitiancarewasassociatedwithlowerrisk assessment tools, including SGA score or Malnutrition Inofmortalityoverthefollow-upperiodof1year. Although flammationScore(MIS). SGAscoreandMISaresimpleand patients without dietitian care are more likely to also lack easily accessible methods that can be used in clinical setnephrologist care, which is a potential confounder, these tings and take approximately 10 minutes. 25 SGA includes results suggest that early nutritional management by a information on nutrient intake; changes in weight; sympspecialized team may improve survival in elderly patients toms affecting oral intake; functional capacity; metabolic with chronic kidney disease. 26 requirement; andphysicalexaminationfindings, including loss of body fat, muscle mass, and presence of Edema. AssessingnutritionalstatussolelyonthebasisofbiochemManagementofNutritioninElderlyPatientswithCKD icalmarkers, suchasalbumin, isnotadvisedbecausethese The initial management of nutrition in chronic kidney disease focuses on markers may be affected by factors other than nutrition, preventive measures to minimize the loss of Protein and including fluid status, systemic inflammation, proteinuria, energystores. Therecommendedminimumdietaryprotein and residual Kidney function. In addition, in this populaandcaloricintakesforpatientswithstage35CKDnoton tion, the presence of Edema and volume expansion due to dialysisareof0. 550. 60g/kgofbodyweightperdayand advancing chronic kidney disease can mask the loss of nutritional reserves, 2535 kcal/kg of body weight per day, respectively. This making body weight an inaccurate measure of nutritional recommendation is supported by measurements of total status. WhileroutinenutritionalscreeningwithSGAorMIS energy expenditure in elderly patients (aged 6086 years) biannually can be completed by any health care provider with chronic kidney disease stage 35 not on Dialysis. 27 and requires minimal training, comprehensive assessment Inspecificcases, higherproteinintakemaybewarranted. toguideintervention ispreferentially providedbyaregisFor patients with Diabetes and chronic kidney disease, a Protein intake of tered dietitian or international equivalent in collaboration 0. 60. 8g/kgperdayisrecommendedtoachieveglycemic withaphysicianorotherproviders(nursepractitionersand control. Patients on RRT, such as Dialysis, may require a physicianassistants). Thisapproach, referredtoasmedical higher Protein intake of 1. 01. 2 g/kg to maintain their Table1. DiagnostictoolsforproteinenergywastinginelderlypatientswithCKD Bodycomposition DEXAisconsideredthegoldstandardfortheassessmentofbodycompositionandcanbeusedin patientswithCKD15D. ItshouldbenotedthatDEXAmeasurementsareaffectedbyvolume statusinpatientsondialysis. Therefore, bioimpedanceorMF-BIAshouldbepreferredin patientsondialysis Biochemicalmarkers Fornutritionalassessment, biochemicalmarkers, includingserumalbumin, prealbuminornPCR, shouldbecoupledwithothertools. Serumalbumincanbeusedforpredictinghospitalization andmortalityinpatientswithCKD5D Handgripstrength Repetitivehandgripstrengthcanbeusedasanindicatorofchangesinfunctionalstatusand proteinenergystatusovertime Energyrequirements Giventhatindirectcalorimetry, thegoldstandardfortheestimationofrestingenergy expenditure, isnotreadilyavailableinmostclinicalsettings, disease-specificpredictiveenergy equationscanbeused Compositenutritionalindices Theseven-pointSGAscoreorMIScanbeusedforCKD5D Measurementofdietaryintake A3-dfoodrecordcanbeusedinpatientswithCKD35D Source: NationalKidneyFoundationDiseaseOutcomesQualityInitiative2020. DEXA, dual-energyx-rayabsorptiometry; MF-BIA, multifrequencybioelectricalimpedance; MIS, MalnutritionInflammationScore; nPCR, normalizedproteincatabolicrate; SGA, SubjectiveGlobalAssessment. KIDNEY3605: 310319, February, 2024 NutritioninGeriatricPatientswithCKD, ErtugluandIkizler 313 nutritional status. 12 Notably, these recommendations may effectsofnutritionalsupplementationinthispopulationis varydependingonindividualpatientfactorsandshouldbe summarized in Table 2. It is important to discuss enteral tailored to each patients specific needs. and parenteral feeding options, including intensity and Incaseswheredietaryintakeisinadequatetoprevent duration, upfrontwithelderlypatientsortheirsurrogates energylossorevidenceofPEW, nutritionalsupplemenbecausetheirgoalsintermsofqualityoflifecoulddiffer. tation is the mainstay of management. The indications for initiation of nutritional intervention and goals of therapyaredemonstratedinFigure2. DietarysupplemenOral Nutritional Supplementation tation should be given by oral route whenever possible Multiple studies examined the effectiveness of oral nu- (Figure 2). Oral supplementation leads to improvement in tritional supplementation (ONS) in the management for biochemical biomarkers, including serum albumin, prealsarcopenia in the elderly population. In general, ONS has buminandtransferrinconcentrations, anthropometricmeabeen shown to benefit elderly patients with evident frailty surements, and functional capacity, as quickly as within a or malnutrition while no benefit has been proven in the month. 17 general older population.",
    "word_count": 600,
    "char_count": 6499,
    "sentence_count": 42,
    "metadata": {
      "source_file": "c3c3c7a683d3d739499c83c2d7b1fbd2a1e0.pdf",
      "extraction_date": "2025-12-31T14:48:10.990845",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2024",
      "keywords": [
        "chronic kidney disease",
        "CKD",
        "dialysis",
        "nephrology"
      ],
      "chunk_index": 2,
      "total_chunks": 9,
      "position": "3/9",
      "content_type": "dietary",
      "content_type_confidence": 8,
      "medical_entities": [
        "chronic kidney disease",
        "kidney function",
        "proteinuria",
        "nutrition",
        "malnutrition",
        "nutrient intake",
        "dietitian",
        "dialysis",
        "edema",
        "screening"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 3,
    "text": "17 general older population. 40 In a recent meta-analysis of 17 If oral route is not feasible because of dysphagia or randomizedclinicaltrials, ONS, givenoncetothreetimesa cognitive dysfunction, enteral tube feeding could be iniday in liquid or solid form, was shown to significantly tiated in select patients. Enteral tube feeding can be improveoverallappetite, energyandproteinintake, aswell administered through nasogastric tubes, percutaneous as body weight and body mass index in the older population with endoscopic gastroscopy, or jejunostomy tubes. There is malnutrition or an underlying disease. 41 Another metano current evidence to support increased benefit from analysis including 11 randomized clinical trials in elderly enteral feeding in elderly patients with chronic kidney disease, and the adults with frailty who were malnourished or at risk of decision for enteral feeding should be individualized malnutrition found little evidence on the effects of ONS considering each patients needs and barriers to oral energy intake, Protein intake, and mobility. 42 The mixed feeding. When oral or enteral intake cannot be tolerated results in the current literature may be attributed to the or is inadequate, parenteral nutrition may be necessary. various definitions of frailty and sarcopenia, as well as Intradialyticparenteralnutrition(IDPN)hasbeenshown inconsistent use of assessment tools and modalities of tobesafeandeffectiveinpatientsonmaintenancehemodiONS. 42 alysis. While the benefits of oral and parenteral nutritional Studies specifically focusing on the elderly population supplementationhavebeenstudiedinvarioussettings, there with chronic kidney disease are limited. Nevertheless, considering that the is limited research specifically investigating their effects in prevalenceofCKDincreaseswithageandthemeanageof thegeriatricCKDpopulation. Theavailableevidenceonthe initiationofmaintenancedialysisinCKDisreportedtobe Nutritional Intervention in Elderly Patients with chronic kidney disease Indications: Goals: (cid: 129) DPI1. 2 or 0. 7 g/kg/d for CKD5D and chronic kidney disease 3-4, (cid: 129) DPI 1. 2 and 0. 7 g/kg/d for chronic kidney disease 5D and chronic kidney disease respectively 3-4, respectively (cid: 129) DEI 30 kcal/kg/d (cid: 129) DEI 30-35 kcal/kg/d (cid: 129) Unintentional weight loss 5% of ideal body (cid: 129) Serum albumin 4 grams per deciliter weight over 3 months (cid: 129) Serum prealbumin 30 milligrams per deciliter (cid: 129) Serum albumin 3. 8 grams per deciliter (cid: 129) Serum prealbumin 28 milligrams per deciliter (cid: 129) 7-point SGA score 6 (cid: 129) Loss of subcutaneous fat stores or muscle mass Special Considerations: (cid: 129) Start with oral nutritional supplementations (ONS) whenever possible. ONS can be taken at home or during hemodialysis sessions. (cid: 129) In cases of no improvement, try increasing the quantity of ONS; consider switching to another ONS preparation on the basis of taste and texture preferences. If adequate oral intake cannot be reached, consider IDPN in patients on hemodialysis. (cid: 129) Consider enteral tube feeding when swallowing is compromised. (cid: 129) Consider parenteral nutrition when gastrointestinal tract is compromised. Figure2. Indications, goals, andspecialconsiderationsfornutritionalinterventioninelderlypatientswithCKD. Table2. StudiesassessingnutritionalinterventionsinelderlypatientswithCKD Sample InclusionandExclusion Intervention Study Time CKDStage MeanAge, yr Aim NutritionalIntervention Outcome Size Criteria ONS Hiroshigeetal. 28 44 12mo Hemodialysis. 70 Exclusioncriteriaincluded Improvementinplasmalevels OralBCAAsupplementforatotal Significantincreaseinlean malnutritionduetofactors ofBCAAandnutritional of12g/d(3. 3g bodymassandserum unrelatedtohemodialysis markers valine, 5. 7gleucine, and albumin andinabilitytoexercise 3gisoleucine) Bolascoetal. 29 30 3mo Hemodialysis 75. 2611. 2 Hemodialysisforatleast6mo, Improvementinnutritional 4gaminoacidsdaily Significantincreaseinserum meanserumalbuminof andinflammatorymarkers albuminandtotalprotein, 3. 5g/dl, normalized withaminoacid proteinnitrogen supplementation appearance, 1. 1g/kgperday, and body mass index. 20kg/m2 Caglaretal. 30 85 6mo Hemodialysis 62. 3615. 4 Hemodialysisforatleast6mo, Improvementinnutritional OneNepro(475calories, 16. 6g Significantincreaseinserum meanserumalbuminof markers Protein, everyhemodialysis albumin, prealbumin, and 3. 7g/dlormeanserum session SGAscoreswith prealbuminof, 30mg/dl intradialytic supplementation Kalantar-Zadehetal. 31 41 4wk Hemodialysis 60. 4613. 0 Hemodialysispatientswith Improvementintheserum OneNepro(475calories, 16. 6g Significantincreaseinthe serumalbumin, 3. 8g/dl albuminlevel Protein)andoneOxepa(355 serumalbuminlevelin caloriesand14. 8gprotein) patientswithbaseline everyhemodialysissession albumin, 3. 8g/dl Ewersetal. 32 40 6wk Hemodialysis 64. 6 Exclusioncriteriaincluded Improvementindietary Oralunsaturatedfatsupplement Significantincreaseindry body mass index. 30kg/m2, serum intake, bloodlipid, and daily(430kcal, 47gfat, 26. 5g bodyweight, serum CRP.",
    "word_count": 597,
    "char_count": 5116,
    "sentence_count": 52,
    "metadata": {
      "source_file": "c3c3c7a683d3d739499c83c2d7b1fbd2a1e0.pdf",
      "extraction_date": "2025-12-31T14:48:10.990845",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2024",
      "keywords": [
        "chronic kidney disease",
        "CKD",
        "dialysis",
        "nephrology"
      ],
      "chunk_index": 3,
      "total_chunks": 9,
      "position": "4/9",
      "content_type": "evidence",
      "content_type_confidence": 7,
      "medical_entities": [
        "chronic kidney disease",
        "nutrition",
        "energy intake",
        "malnutrition",
        "hemodialysis"
      ],
      "entity_count": 5
    }
  },
  {
    "chunk_id": 4,
    "text": "6 Exclusioncriteriaincluded Improvementindietary Oralunsaturatedfatsupplement Significantincreaseindry body mass index. 30kg/m2, serum intake, bloodlipid, and daily(430kcal, 47gfat, 26. 5g bodyweight, serum CRP. 10mg/Lacceptedas nutritionalmarkers monounsaturated, and3g albumin, andCRPlevels anindicationofinfection marinen23polyunsaturated withunsaturatedfat fattyacids) supplementation IDPN Hiroshigeetal. 33 28 12mo Hemodialysis. 70 Age. 70onhemodialysis Improvementinnutritional Parenteralnutritionformula Significantincreasein markers (includingglucose, essential anthropometric aminoacids, fat, 800kcal)every measurements, serum hemodialysissession albumin, andtransferrin Mortelmansetal. 34 16 9mo Hemodialysis 65. 569 Hemodialysisforatleast3mo, Improvementinnutritional Parenteralnutritionformula Significantincreaseinbody weightlossby. 6%over markers (glucose, essentialand weightandfattissuemass 1yroraprealbuminlevel nonessentialaminoacids, fat), 0. 29g/L everyhemodialysissession Liuetal. 35 32 9mo Hemodialysis Control71. 8069. 51 Hemodialysisforatleast3mo, Improvementinnutritional Oralsupplementation, oral Significantlyhigherserum Glucose serumalbumin, 35g/L, markers supplementationplushighalbuminlevelsintheamino 74. 067. 50 serumprealbuminor concentrationglucosesolution acidgroupcomparedwith Aminoacid transferrin, 200mg/Lor andthesetwointerventions theglucosegroupinnon69. 8369. 56 normalizedprotein plus8. 5%aminoacidssolution diabeticpatients decomposition/protein-creatinine ratio everyhemodialysissession, 1. 1g/kgzd 314 KIDNEY360 Table2. (Continued) Sample InclusionandExclusion Intervention Study Time CKDStage MeanAge, yr Aim NutritionalIntervention Outcome Size Criteria Marsenetal. 36 107 4mo Hemodialysis IDPN73. 3611. 8 Hemodialysisforatleast6mo, Improvementinnutritional Parenteralnutritionformula Significantincreaseinserum Control SGAlevelBorCandtwoof markers (glucose, aminoacids, fat, prealbumininpatientswith 75. 068. 48 thefollowingcriteria: vitaminsandtraceelements) protein-energy wasting albumin, 35g/L, everyhemodialysissession prealbumin, 250mg/Lor phaseanglea, 4. 5Â°(BIA analysis) Kittiskulnametal. 37 38 3mo Hemodialysis 67. 6610. 8 Hemodialysisforatleast3mo, Improvementinnutritional Parenteralnutritionformula Significantincreaseinbody spontaneousdietaryintake markers (glucose, aminoacidsandfish weight, serumalbumin, 20kcal/kgperdayand oil-basedlipidemulsionwith spontaneousdietaryintake proteinintake0. 8g/kg omega-3fattyacids, 1100kcal) andMISwithfishoilbased perday, andpresenceof everyhemodialysissession IDPNinpatientswithPEW twoofthefollowing: intolerabletooral albuminlevel supplementation 3. 5g/dl, prealbumin30 milligrams per deciliter, SGAcategoryB, or MIS5points Canoetal. 38 186 1yr Hemodialysis Control67. 2610. 8 Hemodialysisforatleast6mo, All-causemortality, IDPNplusoralsupplementsororal Noadditionalnutritionalor IDPN68. 869. 9 andatleasttwoofthe hospitalizationrate, supplementsalone(IDPN survivalbenefitofIDPN following: body mass index, 20kg/m2, Karnofskyperformance regimenindividualizedtofulfil comparedwithoral bodyweightlosswithin6 score, andnutritional thedifferencebetween supplementationalone mo. 10%, serumalbumin markers spontaneousandrecommended, 35g/L, andserum intakes; oralsupplementation prealbumin, 300mg/L 500kcal/dand25g/dprotein) everyhemodialysissession rhGH Iglesiasetal. 39 17 4wk Hemodialysis 63. 963. 1inthe Peritonealorhemodialysisfor Improvementin Recombinanthuman Significantincreasein andPD rhGHgroup atleast6mo, atleastoneof anthropometricor erythropoietintherapy(weekly anthropometric 58. 365. 6inthe thefollowing: weightloss laboratorynutritional meandose, 102. 8615. 9U/kg measurementsintherhGH controlgroup. 10%inthelast6moor markersandserumIGF-1 subcutaneously) group. 5%inthelastmonth, reductionof. 20%of MAMCand/oridealbody weightaccordingtosex andage, serumalbumin, 4. 0g/dl, protein-creatinine ratio, 0. 9g/kg perday, andlymphocyte count, 1000/ml BCAA, branchedchainaminoacid; BIA, bioelectricalimpedance; body mass index, bodymassindex; CRP, c-reactiveprotein; IDPN, intradialyticparenteralnutrition; IGF-1, insulin-likegrowthfactortype1; MAMC, mid-armmusclecircumference; MIS, malnutrition inflammationscore; ONS, oralnutritionalsupplementation; protein-creatinine ratio, proteincatabolicrate; peritoneal dialysis, peritonealdialysis; rhGH, recombinanthumangrowthhormone; SGA, SubjectiveGlobalAssessment. KIDNEY3605: 310319, February, 2024 NutritioninGeriatricPatientswithCKD, ErtugluandIkizler 315 316 KIDNEY360 6073years, 4345thefindingsofmostnutritionalstudiesin anthropometricmeasurementsafter6monthsoftreatment. chronic kidney disease are applicable to the elderly population with chronic kidney disease. The mean age of the patients receiving IDPN was 8167 Overall, available studies in older patients on mainteyears, andnoadverseeventsrelatedtoIDPNwerereported nance hemodialysis indicate that oral supplementation over 1 year of IDPN. 33 Another study including 107 older is an effective strategy to improve nutritional status in patients (mean age was 73. 3611. 8 years) with underlying this population, albeit the evidence is limited. Commerprotein-energy wasting reported that IDPN significantly increased prealbucially available oral supplement formulations designed for min over 16 weeks while no significant change was obpatientswithCKDtypicallycontainacombinationofamino served in serum albumin orSGA scores. Seven patients in acids, glucose, andfats. Renal-specificsupplementsprovide the IDPN group discontinued therapy because of adverse High Protein and energy content with minimal phosphate events, whichincludedhyperglycemia, musclecrampsdurandpotassium. 46Thesesupplementsmaybegivenathome ing hemodialysis, and gastrointestinal side effects. 36 orduringdialysissessionstoincreasecompliance. Thecost Several studies compared the effects of different formuof commercially available oral supplement formulations lationsofIDPNinelderlypatients. Among36non-diabetic with amino acids is approximately 3 per shake can. elderly hemodialysis patients, the group receiving amino Limited data from small pilot studies suggest that acidbased IDPN had significantly higher albumin levels intradialyticONSadministeredover36monthsimprove compared with the group receiving glucose-based IDPN certainnutritionalmarkers, includingserumalbumin, preafter a treatment period of 9 months. There was no signifalbumin, andSGAscores. 30TheaverageageinthesestudicantchangeinSGAscorescomparedwithbaselineineither ies was around 60 years, and the energy content ranged group. 35 from 475 calories to 830 calories per administration.",
    "word_count": 584,
    "char_count": 6635,
    "sentence_count": 67,
    "metadata": {
      "source_file": "c3c3c7a683d3d739499c83c2d7b1fbd2a1e0.pdf",
      "extraction_date": "2025-12-31T14:48:10.990845",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2024",
      "keywords": [
        "chronic kidney disease",
        "CKD",
        "dialysis",
        "nephrology"
      ],
      "chunk_index": 4,
      "total_chunks": 9,
      "position": "5/9",
      "content_type": "dietary",
      "content_type_confidence": 6,
      "medical_entities": [
        "chronic kidney disease",
        "creatinine",
        "phosphate",
        "malnutrition",
        "insulin",
        "dialysis",
        "hemodialysis",
        "peritoneal dialysis"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 5,
    "text": "35 from 475 calories to 830 calories per administration. In A randomized clinical trial performed in Thailand ingeneral, side-effect profiles were acceptable with gastroincluding 38 patients with protein-energy wasting intolerable to ONS showed testinalissuesinthreepatients; nodropoutswerereported. that Fish oilbased IDPN for 3 months significantly imTheefficacyandsafetyofsupplementationwithspecific proved body weight, serum albumin, spontaneous dietary essential nutrients have also been studied. A crossover intake, and MIS. The beneficial effects on serum albumin study assessed the effects of unsaturated fat dietary supwere maintained at 3 months after the cessation of treatplements on nutritional and inflammatory markers in 40 ment. Themeanagewas67. 6610. 8years, andtwopatients patients on maintenance hemodialysis with a mean age of with manageable hyperglycemia were observed in the 65years. Sixweeksofsupplementation increasedthetotal IDPN group. 37 energyintake(34kcal/kgbodyweightperday)andresulWhile IDPN is valuable in the management of patients ted in significantly increased dry body weight and imwho cannot tolerate adequate oral supplementation, it is proved serum albumin and C-reactive Protein levels. No unlikely to provide additional nutritional benefit when changewasobservedinbloodlipidconcentrationsdespite sufficientoralsupplementationcanbemaintained. Arantheuseoffatsupplements. Theadherencewasworsethan domized trial including 186 patients with a mean age of other studies in patients with chronic kidney disease with seven of the 40 68. 869. 9 years showed that adding IDPN to a regimen patientsdroppingout, fivebecauseofgastrointestinalside of oral supplementation that contained 500 kcal/d and effects, 32 indicating the issues with adherence to ONS. A 25g/dproteindidnotoffernutritionalorsurvivalbenefits pilot clinical trial including 30 patients on hemodialysis in a follow-up period of 2 years. In both groups, body aged75. 2611. 2yearsassessedtheefficacyofaspecialoral weight, serum albumin, and prealbumin increased after amino acid supplementation, including all essential amino 1 year of oral supplementation without the additional acids plus tyrosine and cystine. Among the 15 patients effect of IDPN. 38 randomizedtoreceive12goforalaminoacidsupplementationperday, significantelevationsinserumalbuminand total Protein were seen over 3 months. 29 Oral supplemenAdjunctive Therapies tationofbranched-chainaminoacidsfor6monthswasalso Certain pharmacologic agents, with or without nutrifound to significantly increase lean body mass and serum tional supplements, have been proposed to enhance anaalbumin in patients with chronic kidney disease older than 70 years. 28 bolic activity or stimulate appetite in patients with chronic kidney disease. Theseagentsincluderecombinanthumangrowthhormone (rhGH), nandrolone decanoate (ND), megestrol acetate, IDPN cyproheptadine, melatonin, thalidomide, andghrelin. Most Parenteral infusion of nutrients during Dialysis is a safe ofthesedrugshavenotbeeninvestigatedinelderlypatients and convenient approach for patients who cannot tolerate with chronic kidney disease, but their safety beyond short durations in this oral orenteral administration ofnutrients. Studies suggest population is unclear. thatthecombinationofIDPNwithoralnutritionalsuppleAmong these agents, rhGH has been shown to benefit mentscanimprovemarkersofnutritionalstatus, including nutritional status in various catabolic states, including dry body weight, skinfold measurements, and mid-arm patients on maintenance Dialysis. In adults, rhGH enmuscle circumference, as well as serum albumin and prehances Protein synthesis and reduces proteolysis in the albumin, in patients who cannot reach nutritional goals muscle. Short-term rhGH administration in patients on with oral supplements alone. 28, 36, 37 hemodialysis improves net muscle Protein balance and Earlier studies showed that IDPN can be safely used in increases lean body mass while the effects in the elderly the geriatric population. In a study including 78 elderly patients with chronic kidney disease have not been studied in detail. In a patients older than 70 years, IDPN was found to improve pilot randomized clinical trial in patients with end-stage kidney disease serum albumin and transferrin after 3 months and body withameanageof63. 963. 1years, theadditionofrhGH KIDNEY3605: 310319, February, 2024 NutritioninGeriatricPatientswithCKD, ErtugluandIkizler 317 to dietary prescriptions of 35 kcal/kg and 1 g Protein/kg to availability, tolerability, and elderly patients specific ideal body weight per day for 4 weeks significantly inneeds and wishes. creased dry body weight and transferrin levels compared withdietaryprescriptionalone.",
    "word_count": 584,
    "char_count": 4757,
    "sentence_count": 35,
    "metadata": {
      "source_file": "c3c3c7a683d3d739499c83c2d7b1fbd2a1e0.pdf",
      "extraction_date": "2025-12-31T14:48:10.990845",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2024",
      "keywords": [
        "chronic kidney disease",
        "CKD",
        "dialysis",
        "nephrology"
      ],
      "chunk_index": 5,
      "total_chunks": 9,
      "position": "6/9",
      "content_type": "dietary",
      "content_type_confidence": 6,
      "medical_entities": [
        "chronic kidney disease",
        "supplements",
        "dialysis",
        "hemodialysis",
        "adherence"
      ],
      "entity_count": 5
    }
  },
  {
    "chunk_id": 6,
    "text": "creased dry body weight and transferrin levels compared withdietaryprescriptionalone. 39TheOPPORTUNITYtrial Disclosures assessed the efficacy of 24 months of rhGH treatment in T. A. Ikizler reports the following: Consultancy: Fresenius-Kabi reducing mortality in 695 patients with hypoalbuminemia and Nestle; Research Funding: NIDDK and Veterans Affairs; ondialysis. Thestudywasprematurelyclosedbecauseof Honoraria: Fresenius-KabiandNestle; andAdvisoryorLeadership delayedrecruitmentissues. Theinterimanalysisshowed Role: Kidney International. The remaining author has nothing to that while some cardiovascular risk factors, including disclose. body weight, body fat, serum inflammatory markers, and cholesterol levels, improved in the rhGH arm compared Funding with placebo, there were no differences in all-cause and T. A. Ikizler: USDepartmentofVeteransAffairs(5I01CX001755) cardiovascular mortality, cardiovascular events, or nutriandVanderbiltOBrienKidneyCenter(P30-DK114809). tional markers. 47 Testosterone deficiencyisacommonendocrine disorder AuthorContributions seen in up to 55% of male patients with advanced chronic kidney disease. 48 Conceptualization: T. AlpIkizler. Low serum levels of testosterone in chronic kidney disease are associated Investigation: LaleErtuglu. withexaggeratedsarcopeniaandPEW, aswellasincreased Supervision: T. AlpIkizler. mortality. 49, 50 According to the British Society for Sexual Writingoriginaldraft: LaleErtuglu. Medicine guidelines, testosterone therapy is indicated in Writingreviewediting: LaleErtuglu, T. AlpIkizler. men with symptoms of hypogonadism and total serum testosterone concentration, 8 nmol/L or free testosterone, 180pmol/L. 51Theaimsoftestosteronesupplementation References 1. SabharwalS, WilsonH, ReillyP, GupteCM. Heterogeneityof in chronic kidney disease include improvement of quality of life, muscle thedefinitionofelderlyageincurrentorthopaedicresearch. mass, and functional status. In a recent study including Springerplus. 2015; 4: 516. doi: 10. 1186/s40064-015-1307-x 25 men with stage 34 chronic kidney disease and testosterone deficiency, 2. KoomanJP, KotankoP, ScholsAMWJ, ShielsPG, StenvinkelP. testosterone supplementation with 2% testosterone gel at Chronickidneydiseaseandprematureageing. NatRevNephrol. 2014; 10(12): 732742. doi: 10. 1038/nrneph. 2014. 185 60mg/dfor3monthswasfoundtoimprovesymptomsof 3. RosenbergIH. Sarcopenia: originsandclinicalrelevance. JNutr. hypogonadismaswellasgripstrengthandsenseofphys1997; 127(5suppl): 990S991S. doi: 10. 1093/jn/127. 5. 990S ical well-being. No significant change was seen in body mass index. 52 4. KimJC, Kalantar-ZadehK, KoppleJD. Frailtyandprotein-energy ND, a modified androgenanalog oftestosterone, was also wastinginelderlypatientswithendstagekidneydisease. JAm efficacious in increasing lean body mass and muscle SocNephrol. 2013; 24(3): 337351. doi: 10. 1681/ American Society of Nephrology. 2012010047 strength in patients on Dialysis. 53, 54 Among 29 patients 5. Cruz-JentoftAJ, BaeyensJP, BauerJM, etal. Sarcopenia: Euroon maintenance hemodialysis, treatment with 100 magnesium peanconsensusondefinitionanddiagnosis: reportoftheEuND for 6 months resulted in an increased lean body mass ropeanworkinggrouponsarcopeniainolderpeople. Age and quadriceps muscle cross-sectional area, measured by Ageing. 2010; 39(4): 412423. doi: 10. 1093/ageing/afq034 magnetic resonance imaging. The mean age was 56613 6. FieldingRA, VellasB, EvansWJ, etal. Sarcopenia: anunyears with a wide range of 2688 years. 55 In a phase II diagnosedconditioninolderadults. Currentconsensusdefinition: prevalence, etiology, andconsequences. International dose-finding study, ND increased appendicular lean mass workinggrouponsarcopenia. JAmMedDirAssoc. 2011; 12(4): inadose-responsivemannerupto200mg/wkinmenwith 249256. doi: 10. 1016/j. jamda. 2011. 01. 003 stage5CKD. Themeanageofthepatientsonthehighdose 7. ShafieeG, KeshtkarA, SoltaniA, AhadiZ, LarijaniB, HeshmatR. was 53. 667. 0 years. 56 While testosterone supplementation Prevalenceofsarcopeniaintheworld: asystematicreviewand meta-analysisofgeneralpopulationstudies. JDiabetesMetab maybeaneffectivemanagementtopreventsarcopenia, the Disord. 2017; 16: 21. doi: 10. 1186/s40200-017-0302-x efficacy in the elderly population remains unclear. The 8. LamarcaF, CarreroJJ, RodriguesJCD, BigognoFG, FetterRL, potential side effects, including volume overload, lipid AvesaniCM. Prevalenceofsarcopeniainelderlymaintenance hemodialysispatients: theimpactofdifferentdiagnosticcriteria. disorders, increased risk of thrombosis, and alterations in JNutrHealthAging. 2014; 18(7): 710717. doi: 10. 1007/s12603Liver function tests, should be monitored closely. 014-0505-5 Sarcopenia and protein-energy wasting are highly prevalent in elderly 9. GiglioJ, KamimuraMA, LamarcaF, RodriguesJ, SantinF, patientswithmoderate-to-advancedCKDandisassociated AvesaniCM. Associationofsarcopeniawithnutritionalpawith poor outcome. Multiple factors including reduced rameters, qualityoflife, hospitalization, andmortalityratesof elderlypatientsonhemodialysis. JRenNutr. 2018; 28(3): dietary caloric intake, metabolic and hormonal derange197207. doi: 10. 1053/j. jrn. 2017. 12. 003 ments related to advanced Kidney disease and increasing 10. FouqueD, Kalantar-ZadehK, KoppleJ, etal. Aproposednoage, aswellasvariousbarrierstonutrientintakeincluding menclatureanddiagnosticcriteriaforprotein-energywastingin swallowing dysfunction, cognitive dysfunction, and other acuteandchronickidneydisease. KidneyInt. 2008; 73(4): 391398. doi: 10. 1038/sj. ki. 5002585 social determinants are involved in the development of 11. KoppeL, FouqueD, Kalantar-ZadehK. Kidneycachexiaor these sarcopenia and protein-energy wasting.",
    "word_count": 593,
    "char_count": 5742,
    "sentence_count": 100,
    "metadata": {
      "source_file": "c3c3c7a683d3d739499c83c2d7b1fbd2a1e0.pdf",
      "extraction_date": "2025-12-31T14:48:10.990845",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2024",
      "keywords": [
        "chronic kidney disease",
        "CKD",
        "dialysis",
        "nephrology"
      ],
      "chunk_index": 6,
      "total_chunks": 9,
      "position": "7/9",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "magnesium",
        "caloric intake",
        "dialysis",
        "hemodialysis",
        "quality of life"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 7,
    "text": "ki. 5002585 social determinants are involved in the development of 11. KoppeL, FouqueD, Kalantar-ZadehK. Kidneycachexiaor these sarcopenia and protein-energy wasting. Nutritional status should be Protein-energywastinginchronickidneydisease: factsand assessed and screened routinely by health care providers numbers. JCachexiaSarcopeniaMuscle. 2019; 10(3): 479484. andshouldguidethepreventiveandtherapeuticintervendoi: 10. 1002/jcsm. 12421 tions. Nutritional supplementation is generally effective in 12. IkizlerTA, CuppariL. The2020updatedKDOQIclinical Practiceguidelinesfornutritioninchronickidneydisease. Blood improvingnutritionalstatusandtreatingPEWandshould Purif. 2021; 50(4-5): 667671. doi: 10. 1159/000513698 beadministeredorallyorenterallyasindicated. Nutritional 13. DaiL, MukaiH, LindholmB, etal. Clinicalglobalassessmentof supplementationsshouldbeprescribedwithconsiderations nutritionalstatusaspredictorofmortalityinchronickidney 318 KIDNEY360 diseasepatients. PLoSOne. 2017; 12(12): e0186659. doi: malnutritionandinflammationinhemodialysispatients. JRen 10. 1371/journal. pone. 0186659 Nutr. 2009; 19(5): 401411. doi: 10. 1053/j. jrn. 2009. 04. 006 14. de Mutsert R, Grootendorst DC, Boeschoten EW, et al. 33. HiroshigeK, IwamotoM, KabashimaN, MutohY, YuuK, Ohtani Subjective global assessment of nutritional status is strongly A. Prolongeduseofintradialysisparenteralnutritioninelderly associated with mortality in chronic Dialysis patients. Am J malnourishedchronichaemodialysispatients. NephrolDial Clin Nutr. 2009; 89(3): 787793. doi: 10. 3945/ Transplant. 1998; 13(8): 20812087. doi: 10. 1093/ndt/13. 8. 2081 ajcn. 2008. 26970 34. MortelmansAK, DuymP, VandenbrouckeJ, etal. Intradialytic 15. ZhouY, HellbergM, SvenssonP, HoglundP, ClyneN. Sarcoparenteralnutritioninmalnourishedhemodialysispatients: a peniaandrelationshipsbetweenmusclemass, measuredgloprospectivelong-termstudy. JPENJParenterEnteralNutr. 1999; merularfiltrationrateandphysicalfunctioninpatientswith 23(2): 9095. doi: 10. 1177/014860719902300290 chronickidneydiseasestages35. NephrolDialTransplant. 35. LiuY, XiaoX, QinDP, etal. Comparisonofintradialyticpar2018; 33(2): 342348. doi: 10. 1093/ndt/gfw466 enteralnutritionwithglucoseoraminoacidmixturesinmain16. IkizlerTA. Optimalnutritioninhemodialysispatients. Adv tenancehemodialysispatients. Nutrients. 2016; 8(6): 220. doi: ChronicKidneyDis. 2013; 20(2): 181189. doi: 10. 1053/ 10. 3390/nu8060220 j. ackd. 2012. 12. 002 36. MarsenTA, BeerJ, MannH. ; GermanIDPN-Trialgroup. Intra17. IkizlerTA, CanoNJ, FranchH, etal. Preventionandtreatmentof dialyticparenteralnutritioninmaintenancehemodialysispaproteinenergywastinginchronickidneydiseasepatients: a tientssufferingfromprotein-energywasting. ResultsofamulconsensusstatementbytheInternationalSocietyofRenalNu- ticenter, open, prospective, randomizedtrial. ClinNutr. 2017; tritionandMetabolism. KidneyInt. 2013; 84(6): 10961107. doi: 36(1): 107117. doi: 10. 1016/j. clnu. 2015. 11. 016 10. 1038/ki. 2013. 147 37. KittiskulnamP, BanjongjitA, MettaK, etal. Thebeneficialeffects 18. BossolaM, TazzaL, GiungiS, LucianiG. Anorexiainhemoofintradialyticparenteralnutritioninhemodialysispatientswith dialysispatients: anupdate. KidneyInt. 2006; 70(3): 417422. proteinenergywasting: aprospectiverandomizedcontrolled doi: 10. 1038/sj. ki. 5001572 trial. SciRep. 2022; 12(1): 4529. doi: 10. 1038/s41598-02219. DegerSM, HungAM, GamboaJL, etal. Systemicinflammationis 08726-8 associatedwithexaggeratedskeletalmuscleproteincatabolism 38. CanoNJ, FouqueD, RothH, etal. Intradialyticparenteralnuinmaintenancehemodialysispatients. JCIInsight. 2017; 2(22): tritiondoesnotimprovesurvivalinmalnourishedhemodialysis e95185. doi: 10. 1172/jci. insight. 95185 patients: a2-yearmulticenter, prospective, randomizedstudy. J 20. HondaH, QureshiAR, AxelssonJ, etal. Obesesarcopeniain AmSocNephrol. 2007; 18(9): 25832591. doi: 10. 1681/ patientswithend-stagerenaldiseaseisassociatedwithinAmerican Society of Nephrology. 2007020184 flammationandincreasedmortality. AmJClinNutr. 2007; 86(3): 39. IglesiasP, DÄ±ezJJ, Fernandez-ReyesMJ, etal. Recombinant 633638. doi: 10. 1093/ajcn/86. 3. 633 humangrowthhormonetherapyinmalnourisheddialysispa21. SouzaVA, OliveiraD, BarbosaSR, etal. Sarcopeniainpatients tients: arandomizedcontrolledstudy. AmJKidneyDis. 1998; withchronickidneydiseasenotyetondialysis: analysisofthe 32(3): 454463. doi: 10. 1053/ajkd. 1998. v32. pm9740162 prevalenceandassociatedfactors. PLoSOne. 2017; 12(4): 40. GammackJK, SanfordAM. Caloricsupplementsfortheelderly. e0176230. doi: 10. 1371/journal. pone. 0176230 CurrOpinClinNutrMetabCare. 2015; 18(1): 3236. doi: 22. LandiF, CalvaniR, TosatoM, etal. Anorexiaofaging: risk 10. 1097/MCO. 0000000000000125 factors, consequences, andpotentialtreatments. Nutrients. 41. LiM, ZhaoS, WuS, YangX, FengH. Effectivenessoforal 2016; 8(2): 69. doi: 10. 3390/nu8020069 nutritionalsupplementsonolderpeoplewithanorexia: asys23. RoubenoffR. Sarcopeniaanditsimplicationsfortheelderly. EurJ tematicreviewandmeta-analysisofrandomizedcontrolled ClinNutr. 2000; 54(suppl3): S40S47. doi: 10. 1038/ trials. Nutrients. 2021; 13(3): 835. doi: 10. 3390/nu13030835 sj. ejcn. 1601024 42. ThomsonKH, RiceS, ArisaO, etal. Effectivenessandcost24. DhillonRJ, HasniS. Pathogenesisandmanagementofsarcoeffectivenessoforalnutritionalsupplementsinfrailolderpeople penia. ClinGeriatrMed. 2017; 33(1): 1726. doi: 10. 1016/ whoaremalnourishedoratriskofmalnutrition: asystematic j. cger. 2016. 08. 002 reviewandmeta-analysis. LancetHealthyLongev. 2022; 3(10): 25. RambodM, BrossR, ZitterkophJ, etal. Associationof e654e666. doi: 10. 1016/S2666-7568(22)00171-4 Malnutrition-InflammationScorewithqualityoflifeandmor43. BonenkampAA, HoekstraT, HemmelderMH, etal. Trendsin talityinhemodialysispatients: a5-yearprospectivecohortstudy. homedialysisusedifferamongagecategoriesinpasttwodeAmJKidneyDis. 2009; 53(2): 298309. doi: 10. 1053/ cades: aDutchregistrystudy. EurJClinInvest. 2022; 52(1): j. ajkd. 2008. 09. 018 e13656. doi: 10. 1111/eci. 13656 26. SlininY, GuoH, GilbertsonDT, etal. Prehemodialysiscareby 44. FuEL, EvansM, CarreroJJ, etal. Timingofdialysisinitiationto dietitiansandfirst-yearmortalityafterinitiationofhemodialysis. reducemortalityandcardiovasculareventsinadvancedchronic AmJKidneyDis. 2011; 58(4): 583590. doi: 10. 1053/ kidneydisease: nationwidecohortstudy. BMJ. 2021; 375: j. ajkd. 2011. 03. 032 e066306. doi: 10. 1136/bmj-2021-066306 27. DAlessandroC, GianneseD, AvinoM, CupistiA. Energyre45. CooperBA, BranleyP, BulfoneL, etal. Arandomized, controlled quirementforelderlyCKDpatients. Nutrients. 2021; 13(10): trialofearlyversuslateinitiationofdialysis. NewEnglJMed. 3396. doi: 10. 3390/nu13103396 2010; 363(7): 609619. doi: 10. 1056/NEJMoa1000552 28. HiroshigeK, SontaT, SudaT, KanegaeK, OhtaniA. Oral 46. MahJY, ChoySW, RobertsMA, etal. Oralprotein-basedsupsupplementationofbranched-chainaminoacidimproves plementsforpeoplewithchronickidneydiseaserequiringdinutritionalstatusinelderlypatientsonchronichaemodialysis. alysis. CochraneDatabaseSystRev. 2017; 2017(3): CD012616. NephrolDialTransplant. 2001; 16(9): 18561862. doi: 10.",
    "word_count": 600,
    "char_count": 7129,
    "sentence_count": 218,
    "metadata": {
      "source_file": "c3c3c7a683d3d739499c83c2d7b1fbd2a1e0.pdf",
      "extraction_date": "2025-12-31T14:48:10.990845",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2024",
      "keywords": [
        "chronic kidney disease",
        "CKD",
        "dialysis",
        "nephrology"
      ],
      "chunk_index": 7,
      "total_chunks": 9,
      "position": "8/9",
      "content_type": "dietary",
      "content_type_confidence": 7,
      "medical_entities": [
        "malnutrition",
        "dialysis"
      ],
      "entity_count": 2
    }
  },
  {
    "chunk_id": 8,
    "text": "Oral 46. MahJY, ChoySW, RobertsMA, etal. Oralprotein-basedsupsupplementationofbranched-chainaminoacidimproves plementsforpeoplewithchronickidneydiseaserequiringdinutritionalstatusinelderlypatientsonchronichaemodialysis. alysis. CochraneDatabaseSystRev. 2017; 2017(3): CD012616. NephrolDialTransplant. 2001; 16(9): 18561862. doi: 10. 1093/ doi: 10. 1002/14651858. CD012616 ndt/16. 9. 1856 47. KoppleJD, CheungAK, ChristiansenJS, etal. OPPORTUNI29. BolascoP, CariaS, CupistiA, SecciR, SaverioDioguardiF. A TYtrade; : alarge-scalerandomizedclinicaltrialofgrowth novelaminoacidsoralsupplementationinhemodialysispahormoneinhemodialysispatients. NephrolDialTransplant. tients: apilotstudy. RenFail. 2011; 33(1): 15. doi: 10. 3109/ 2011; 26(12): 40954103. doi: 10. 1093/ndt/gfr363 0886022X. 2010. 536289 48. AlbaajF, SivalinghamM, HaynesP, etal. Prevalenceof 30. CaglarK, FedjeL, DimmittR, HakimRM, ShyrY, IkizlerTA. hypogonadisminmalepatientswithrenalfailure. PostgradMed Therapeuticeffectsoforalnutritionalsupplementationduring J. 2006; 82(972): 693696. doi: 10. 1136/pgmj. 2006. 045963 hemodialysis. KidneyInt. 2002; 62(3): 10541059. doi: 10. 1046/ 49. RomejkoK, RymarzA, SadownikH, NiemczykS. Testosterone j. 1523-1755. 2002. 00530. x deficiencyasoneofthemajorendocrinedisordersinchronic 31. Kalantar-ZadehK, BragliaA, ChowJ, etal. Ananti-inflammatory kidneydisease. Nutrients. 2022; 14(16): 3438. doi: 10. 3390/ andantioxidantnutritionalsupplementforhypoalbuminemic nu14163438 hemodialysispatients: apilot/feasibilitystudy. JRenNutr. 2005; 50. SkibaR, MatyjekA, SyryÅoT, NiemczykS, RymarzA. Advanced 15(3): 318331. doi: 10. 1016/j. jrn. 2005. 04. 004 chronickidneydiseaseisastrongpredictorofhypogonadism 32. EwersB, RiserusU, MarckmannP. Effectsofunsaturatedfat andisassociatedwithdecreasedleantissuemass. IntJNephrol dietarysupplementsonbloodlipids, andonmarkersof RenovascDis. 2020; 13: 319327. doi: 10. 2147/IJNRD. S275554 KIDNEY3605: 310319, February, 2024 NutritioninGeriatricPatientswithCKD, ErtugluandIkizler 319 51. HackettG, KirbyM, EdwardsD, etal. BritishSocietyforSexual randomizedcontrolledtrial. JAMA. 1999; 281(14): 12751281. medicineguidelinesonadulttestosteronedeficiency, with doi: 10. 1001/jama. 281. 14. 1275 statementsforUKpractice. JSexMed. 2017; 14(12): 15041523. 55. JohansenKL, PainterPL, SakkasGK, GordonP, DoyleJ, ShubertT. doi: 10. 1016/j. jsxm. 2017. 10. 067 Effectsofresistanceexercisetrainingandnandrolonedecanoate 52. YeoJK, KooHS, YuJ, ParkMG. Effectsoftestosteronetreatment onbodycompositionandmusclefunctionamongpatientswho onqualityoflifeinpatientswithchronickidneydisease. AmJ receivehemodialysis: arandomized, controlledtrial. JAmSoc MensHealth. 2020; 14(3): 1557988320917258. doi: 10. 1177/ Nephrol. 2006; 17(8): 23072314. doi: 10. 1681/American Society of Nephrology. 2006010034 1557988320917258 56. MacdonaldJH, MarcoraSM, JibaniMM, KumwendaMJ, Ahmed 53. BartonPaiA, ChretienC, LauAH. Theeffectsofnandrolone W, LemmeyAB. Nandrolonedecanoateasanabolictherapyin decanoate on nutritional parameters in hemodialysis pachronickidneydisease: arandomizedphaseIIdose-finding tients. Clin Nephrol. 2002; 58(1): 3846. doi: 10. 5414/ study. NephronClinPract. 2007; 106(3): c125c135. doi: cnp58038 10. 1159/000103000 54. JohansenKL, MulliganK, SchambelanM. Anaboliceffectsof nandrolonedecanoateinpatientsreceivingdialysis: a PublishedOnlineAheadofPrint: February1, 2024",
    "word_count": 289,
    "char_count": 3395,
    "sentence_count": 102,
    "metadata": {
      "source_file": "c3c3c7a683d3d739499c83c2d7b1fbd2a1e0.pdf",
      "extraction_date": "2025-12-31T14:48:10.990845",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2024",
      "keywords": [
        "chronic kidney disease",
        "CKD",
        "dialysis",
        "nephrology"
      ],
      "chunk_index": 8,
      "total_chunks": 9,
      "position": "9/9",
      "content_type": "dietary",
      "content_type_confidence": 5,
      "medical_entities": [
        "hemodialysis"
      ],
      "entity_count": 1
    }
  }
]